In This Article:
Morgan Stanley analyst David Bailey initiated coverage of ResMed (RMD) with an Overweight rating and $280 price target The company has a market-leading position in the obstructive sleep apnea market and valuations appear attractive at current levels, with a strong balance sheet position and the highest ROIC across the firm’s Australian Healthcare industry sector coverage, the analyst tells investors.
Light Up your Portfolio with Spark:
-
Easily identify stocks' risks and opportunities.
-
Discover stocks' market position with detailed competitor analyses.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RMD:
Questions or Comments about the article? Write to editor@tipranks.com